

## References

### S-152

1. InterQual® Level of Care Criteria 2019, Acute Care Adult, McKesson Health Solutions, LLC.
2. Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: A systematic review and meta-analysis. *Ann Intern Med.* 2018;168(5):335-342.
3. De Rosa S, Sievert H, Sabatino J, et al. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: A systematic review and meta-analysis. *Ann Intern Med.* 2018;168(5):343-350.
4. S. Food and Drug Administration. Summary of safety and effectiveness data. Gore Cardioform Septal Occluder. March 30, 2018. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf5/P050006s060b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050006s060b.pdf). Accessed June 03, 2021
5. Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED): Patent Foramen Ovale (PFO) occluder (PMA P120021). 2016; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf12/P120021B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120021B.pdf). Accessed June 03, 2021.
6. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: The defense-PFO trial. *J Am Coll Cardiol.* 2018;71(20):2335-2342.
7. Alushi B, Lauten A, Cassese S, et al. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: Updated meta-analysis of randomized clinical trials. *Clin Res Cardiol.* 2018;107(9):788-798.
8. Wintzer-Wehekind J, Alperi A, Houde C, et al. Long-term follow-up after closure of patent foramen ovale in patients with cryptogenic embolism. *J Am Coll Cardiol.* 2019;73(3):278-287.
9. Tobis JM, Charles A, Silberstein SD, et al. Percutaneous closure of patent foramen ovale in patients with migraine: The premium trial. *J Am Coll Cardiol.* 2017;70(22):2766-2774
10. Jalal Z, Hascoet S, Gronier C, et al. Long-term outcomes after percutaneous closure of ostium secundum atrial septal defect in the young: A nationwide cohort study. *JACC Cardiovasc Interv.* 2018;11(8):795-804.
11. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;73(12):e81-e192.

12. Kashyap T, Sanusi M, Momin ES, et al. Transcatheter occluder devices for the closure of atrial septal defect in children: How safe and effective are they? A systematic review. *Cureus*. 2022;14(5):e25402.
13. Musto C, Cifarelli A, Dipasquale F, et al. A comparison between gore cardioform and amplatzer septal occluder for percutaneous closure of patent foramen ovale associated with atrial septal aneurysm: Clinical and echocardiographic outcomes. *J Invasive Cardiol*. 2021;33(11):E857-E862
14. Kumar V, Ward C, Justo R, et al. The gore septal occluder (GSO) for multiple indications in children - An intention to treat analysis. *Heart Lung Circ*. 2021;30(10):1578-1581.
15. Santoro G, Castaldi B, Cuman M, et al. Trans-catheter atrial septal defect closure with the new GORE® Cardioform ASD occluder: First European experience. *Int J Cardiol*. 2021;327:68-73.